Community health experts call for balanced approach to continued development of promising new TB drug in a new article. They argue that research into bedaquiline — a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) — should proceed cautiously in people with drug-sensitive tuberculosis.